Role of B cells in anti-PD-(L)1 therapy in tumor bearing mice

Junlei HOU; Xuezhi YANG; Fen DONG; Haoran ZHA; Fei YANG; Bo ZHU

doi:10.16016/j.2097-0927.202401015

您当前的位置：

首页 >

文章列表页 >

Role of B cells in anti-PD-(L)1 therapy in tumor bearing mice

Basic Medicine | 更新时间：2026-01-09

- Role of B cells in anti-PD-(L)1 therapy in tumor bearing mice
- Journal of Army Medical University Vol. 46, Issue 8, Pages: 804-814(2024)
- 作者机构：
  
  1.400037 重庆，陆军军医大学(第三军医大学)第二附属医院全军肿瘤研究所
  2.130062 长春，解放军第九六四医院放射科
  3.400054 重庆，重庆理工大学药学与生物工程学院
  4.100088 北京，解放军火箭军特色医学中心肿瘤科
- 作者简介：
- 基金信息：
  
  the General Program of National Natural Science Foundation of China(82272808)
- DOI：10.16016/j.2097-0927.202401015
  CLC： R392.12;R730.51;R739.5
- Received：04 January 2024，
  
  Revised：2024-03-04，
  
  Published：30 April 2024
- 稿件说明：
移动端阅览
Junlei HOU, Xuezhi YANG, Fen DONG, et al. Role of B cells in anti-PD-(L)1 therapy in tumor bearing mice[J]. Journal of Army Medical University, 2024, 46(8): 804-814.
DOI：

Junlei HOU, Xuezhi YANG, Fen DONG, et al. Role of B cells in anti-PD-(L)1 therapy in tumor bearing mice[J]. Journal of Army Medical University, 2024, 46(8): 804-814. DOI： 10.16016/j.2097-0927.202401015.

摘要

目的

探讨肿瘤浸润性B细胞对程序性死亡受体(配体)1[programmed death (ligand) 1

PD-(L)1]抑制剂治疗效果的影响，阐明B细胞影响免疫治疗的潜在机制。

方法

通过使用公共数据库中的黑色素瘤患者免疫治疗队列，分析B细胞与无进展生存时间(progression-free survival，PFS)以及免疫治疗响应的关系；使用TC-1和B16-OVA肿瘤细胞对6~8周龄雌性C57BL/6小鼠的皮下及肝脏进行荷瘤，构建肿瘤模型。比较B细胞清除对PD-(L)1抗体治疗效果的影响；对第15天的TC-1肿瘤微环境(tumor microenvironment，TME)进行流式细胞术检测，明确T细胞的数目、功能及表型变化；通过流式细胞术及实时荧光定量聚合酶链式反应(quantitative real-time polymerase chain reaction，qPCR)检测B细胞表面分子以及细胞因子。

结果

基于ICBatlas公共数据库中的ERP105482数据分析，肿瘤中CD19高表达的黑色素瘤患者PFS较低表达者更长(753 d

95 d，

=0.3，95%

: 0.13~0.65，

=0.003)。B细胞在免疫治疗应答的患者中显著富集(

=0.01)。在小鼠TC-1肝脏荷瘤模型中，PD-(L)1抗体治疗后肿瘤质量明显减小(

＜0.01)，而B细胞的清除削弱了治疗效果。B细胞通过促进T细胞浸润和功能来增强PD-(L)1抗体治疗，且治疗后B细胞亚群发生变化，表现为PD-1低表达亚群增加(

＜0.01)。

结论

PD-(L)1抗体治疗后，B细胞亚群中PD-1表达的下降可能是B细胞促进PD-(L)1抗体治疗效果的潜在机制。

Abstract

Objective

To investigate the effect of tumor-infiltrating B cells on the therapeutic efficacy of programmed death ligand-1 [PD-(L)1] inhibitors and elucidate the potential mechanisms.

Methods

Based on immunotherapy cohorts for melanoma patients in public databases

the relationship of B cells with progression-free survival (PFS) and response to immune checkpoint inhibitors treatment was analyzed. TC-1 and B16-OVA cells were implanted subcutaneously and in the liver in 6-8-week-old female C57BL/6 mice to establish tumor xenograft models. The effect of B cell clearance on PD-(L)1 therapy was compared. Flow cytometry was performed on the 15th day of TC-1 tumor microenvironment (TME) to confirm the number

function and phenotypic changes of T cells. Flow cytometry and quantitative real-time polymerase chain reaction (qPCR) were used to detect B cell surface molecules and cytokines.

Results

Based on ERP105482 data from the ICBatlas public database

high CD19 expression in the tumors was associated with longer PFS in melanoma patients (753

95 d

=0.3

95%

: 0.13~0.65

=0.003). B cells were significantly enriched in immunotherapy-responsive patients (

=0.01). In a mouse TC-1 liver-loaded tumor model

PD-(L)1 antibody treatment reduced tumor mass (

0.01)

whereas B-cell clearance attenuated the therapeutic efficacy. B cells enhanced PD-(L)1 antibody treatment by promoting T cell infiltration and function

and the treatment resulted in changes in B cell subsets

as evidenced by an increase in PD-1 low-expressing subsets (

0.01).

Conclusion

After PD-(L)1 treatment

a decrease in PD-1 expression on B cell subsets might be one of the potential mechanisms by which B cells enhance the efficacy of PD-(L)1 therapy.

关键词

Keywords

references

ANTONIA S, GOLDBERGS B, BALMANOUKIAN A, et al . Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study[J ] . Lancet Oncol, 2016, 17(3): 299-308. DOI: 10.1016/S1470-2045(15)00544-6.

GIDET N, QUEK C, MENZIES A M, et al . Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy[J ] . Cancer Cell, 2019, 35(2): 238-255.e6. DOI: 10.1016/j.ccell.2019.01.003.

NAKAMURA T, SATO T, ENDO R, et al . STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation[J ] . J Immunother Cancer, 2021, 9(7): e002852. DOI: 10.1136/jitc-2021-002852.

THORSSON V, GIBBSD L, BROWN S D, et al . The immune landscape of cancer[J ] . Immunity, 2018, 48(4): 812-830.e14. DOI: 10.1016/j.immuni.2018.03.023.

LAUMONTC M, BANVILLE A C, GILARDI M, et al . Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities[J ] . Nat Rev Cancer, 2022, 22(7): 414-430. DOI: 10.1038/s41568-022-00466-1.

PETITPREZ F, DE REYNIÈS A, KEUNG E Z, et al . B cells are associated with survival and immunotherapy response in sarcoma[J ] . Nature, 2020, 577(7791): 556-560. DOI: 10.1038/s41586-019-1906-8.

HELMINKB A, REDDY S M, GAO J J, et al . B cells and tertiary lymphoid structures promote immunotherapy response[J ] . Nature, 2020, 577(7791): 549-555. DOI: 10.1038/s41586-019-1922-8.

CABRITA R, LAUSS M, SANNA A, et al . Tertiary lymphoid structures improve immunotherapy and survival in melanoma[J ] . Nature, 2020, 577(7791): 561-565. DOI: 10.1038/s41586-019-1914-8.

GRISS J, BAUER W, WAGNER C, et al . B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma[J ] . Nat Commun, 2019, 10(1): 4186. DOI: 10.1038/s41467-019-12160-2.

LU Y W, ZHAO Q Y, LIAO J Y, et al . Complement signals determine opposite effects of B cells in chemotherapy-induced immunity[J ] . Cell, 2020, 180(6): 1081-1097.e24. DOI: 10.1016/j.cell.2020.02.015.

KANSAL V, BURNHAMA J, KINNEY B L C, et al . Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models[J ] . J Immunother Cancer, 2023, 11(1): e005940. DOI: 10.1136/jitc-2022-005940.

ZHU J J, NAULAERTS S, BOUDHAN L, et al . Tumour immune rejection triggered by activation of α2-adrenergic receptors[J ] . Nature, 2023, 618(7965): 607-615. DOI: 10.1038/s41586-023-06110-8.

DAMSKY W, JILAVEANU L, TURNER N, et al . B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors[J ] . J Immunother Cancer, 2019, 7(1): 153. DOI: 10.1186/s40425-019-0613-1.

LADÁNYI A, KISS J, MOHOS A, et al . Prognostic impact of B-cell density in cutaneous melanoma[J ] . Cancer Immunol Immunother, 2011, 60(12): 1729-1738. DOI: 10.1007/s00262-011-1071-x.

BOD L, KYEY C, SHI J W, et al . B-cell-specific checkpoint molecules that regulate anti-tumour immunity[J ] . Nature, 2023, 619(7969): 348-356. DOI: 10.1038/s41586-023-06231-0.

NAYAR S, PONTARINI E, CAMPOS J, et al . Immunofibroblasts regulate LTα3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction[J ] . Commun Biol, 2022, 5(1): 413. DOI: 10.1038/s42003-022-03344-6.

HONG S, ZHANG Z M, LIU H T, et al . B cells are the dominant antigen-presenting cells that activate naive CD4 + T cells upon immunization with a virus-derived nanoparticle antigen[J ] . Immunity, 2018, 49(4): 695-708.e4. DOI: 10.1016/j.immuni.2018.08.012..

WENNHOLD K, THELEN M, LEHMANN J, et al . CD86 + antigen-presenting B cells are increased in cancer, localize in tertiary lymphoid structures, and induce specific T-cell responses[J ] . Cancer Immunol Res, 2021, 9(9): 1098-1108. DOI: 10.1158/2326-6066.CIR-20-0949..

RICKLIN D, HAJISHENGALLIS G, YANG K, et al . Complement: a key system for immune surveillance and homeostasis[J ] . Nat Immunol, 2010, 11(9): 785-797. DOI: 10.1038/ni.1923.

CARROLLM C, ISENMAN D E. Regulation of humoral immunity by complement[J]. Immunity, 2012, 37(2): 199-207. DOI: 10.1016/j.immuni.2012.08.002.

WU H, XIA L M, JIA D D, et al . PD-(L)1 + regulatory B cells act as a T cell suppressor in a PD-(L)1-dependent manner in melanoma patients with bone metastasis[J ] . Mol Immunol, 2020, 119: 83-91. DOI: 10.1016/j.molimm.2020.01.008..

SHALAPOUR S, FONT-BURGADA J, DI CARO G, et al . Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy[J ] . Nature, 2015, 521(7550): 94-98. DOI: 10.1038/nature14395.

HARRISR J, WILLSMORE Z, LADDACH R, et al . Enriched circulating and tumor-resident TGF-β + regulatory B cells in patients with melanoma promote FOXP3 + Tregs[J ] . Oncoimmunology, 2022, 11(1): 2104426. DOI: 10.1080/2162402X.2022.2104426..

XIAO X, LAOX M, CHEN M M, et al . PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression[J ] . Cancer Discov, 2016, 6(5): 546-559. DOI: 10.1158/2159-8290.CD-15-1408.

Views

118

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Vismodegib regulates microenvironment of basal cell carcinoma via BRD9-mediated Hedgehog and PD-L1 signaling

Characterizing tumor nicroenvironment features and identifying potential therapeutic targets in patients with diabetes mellitus and pancreatic cancer based on single-cell transcriptome sequencing

Features of tumor cells and microenvironment associated with recurrence risk of mesenchymal-subtype gastric cancer based on bulk RNA-seq and scRNA-seq

Plateau hypoxia improves tumor immune microenvironment and inhibits subcutaneous tumor growth of colorectal cancer

Related Author

PENG Ziyi

ZHANG Yongchao

LIU Zhenkun

XIANG Junyu

LI Xianfeng

QIU Qiu

WANG Bin

WANG Hao

Related Institution

Department of Gastroenterology， Chongqing Hechuan People’s Hospital

Department of Cell Biology， College of Basic Medical Sciences， Army Medical University （Third Military Medical University）

Department of Gastroenterology， Chongqing Key Laboratory of Precise Prevention and Treatment of Digestive Malignancies， Daping Hospital， Army Medical University（Third Military Medical University）

College of Medical Laboratory Science， Jilin Medical University

重庆大学医学院

⁰